Research
Hormonal
Sleep restriction (4-5 hours per night) impairs glucose tolerance and insulin sensitivity, increasing the risk of type 2 diabetes and metabolic disorders.
Chronic sleep restriction impairs your body's ability to process glucose, increasing diabetes risk. Prioritize 7-8 hours of sleep to maintain healthy insulin sensitivity and glucose metabolism.
StrongSupportsHIGH confidence
Glucose tolerance was 40% lower at the end of the sleep restriction period than after sleep extension. The insulin profile showed a biphasic pattern with the first phase (corresponding to the rapid release of insulin from the β cells) reduced by 30%, as was the level of C-peptide by 25%. Glucose effectiveness, a measure of non-insulin-dependent glucose uptake, was also reduced by 30% – 40%.
Why this rating
Based on controlled experimental studies with objective metabolic measurements.
Source
Sleep debt and obesity
Virginie Bayon et al. · Annals of Medicine · 2014
DOI 10.3109/07853890.2014.931103
narrative_reviewCited 239×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Sleep restriction (4-5 hours per night) causes hormonal changes characterized by decreased leptin and increased ghrelin, leading to increased hunger, appetite, and a preference for high-carbohydrate and high-fat foods.Strong
- Short sleep duration (less than 6 hours per night) is associated with increased body mass index (BMI) and obesity risk, with a stronger and more consistent association observed in children and young adults compared to older adults.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →